| Name | Bucladesine sodium |
| Description | Bucladesine sodium (DC2797) is a cAMP analog with cell-permeable properties. Bucladesine sodium is also a cAMP-dependent protein kinase (PKA) activator and a phosphodiester (PDE) inhibitor. Bucladesine sodium has anti-inflammatory activity. |
| Animal Research | Animal: Mice. Formulation: water/DMSO (9:1). Dosages: 600 nM. Administration: i.p. |
| In vitro | METHODS: Human eosinophil EoL-1 cells were treated with Bucladesine sodium (10-100 µM) for 8 days and activity was measured using PKA assay.
RESULTS: Proliferation of EoL-1 cells treated with Bucladesine sodium increased in a time-dependent manner. [1]
METHODS: PC12 cells were treated with Bucladesine sodium (1 mM) for 72 h. TNF-α levels were measured by ELISA assay.
RESULTS: Bucladesine sodium increased the activity of PKA. [2] |
| In vivo | METHODS: To study the anti-inflammatory activity in vivo, Bucladesine sodium (0.24-0.7 µg/kg) was administered intraperitoneally to a mouse model of copper pine demyelination once daily for seven days.
RESULTS: Bucladesine had a protective effect on myelin formation. Enhanced intracellular cAMP prevented demyelination and exerted anti-inflammatory and anti-apoptotic properties in a mouse model of copper pine demyelination. [3]
METHODS: To investigate the effects on liver injury, Bucladesine sodium (0.5-500 mg/kg) was intraperitoneally injected into C57BL/6J jcl mice, and liver injury was induced by the intravenous injection of rTNF-α (1.0 µg/kg) and intraperitoneal injection of D-gal (500 mg/kg) after 1 h. The RESULTS showed that Bucladesine protected against hepatic injury in C57BL/6J jcl mice.
RESULTS: Bucladesine protected mice from TNF-α/D-gal-induced liver injury.Bucladesine significantly enhanced the expression of Hsp70 in hepatocytes of D-gal/TNFα-injected mice, which was closely related to the inhibition of liver injury. [4] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 200 mg/mL (407.03 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (8.14 mM), Sonication is recommended.
DMSO : 144 mg/mL (293.06 mM), Sonication is recommended.
|
| Keywords | VAChT | spatial | Protein kinase A | PKA | Phosphodiesterase (PDE) | phosphodiesterase | memory | lipophilic | intracellular | Inhibitor | inhibit | Dibutyryl-cAMP sodium | Dibutyryl cAMP | DC-2797 | DC 2797 | ChAT | cAMP | CA1 | Bucladesine sodium | anti-inflammatory |
| Inhibitors Related | Undecane | Balipodect | Rhamnose monohydrate | D(+)-Raffinose pentahydrate | Theobromine | Apremilast | Isoprenaline hydrochloride | Indomethacin | D-Mannitol | Isovaleric acid | Sildenafil citrate | Doxofylline |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Kinase Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |
United States
